NEW YORK, March 20, 2018 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, has published a negative report
The full report can be found at http://kerr.co/pti.
Kerrisdale has a short position in Proteostasis Therapeutics, Inc., and stands to benefit if its share price falls.
Conference Call ScheduleKerrisdale will host a conference call on Tuesday, March 20 at 10:30am ET to discuss the Proteostasis report.
To participate in the conference call, dial (866) 834-3313 (United States) or (409) 981-0700 (international) and reference the Kerrisdale Capital call.
About Kerrisdale CapitalKerrisdale Capital Management, LLC, is a fundamentally-oriented investment manager that focuses on long-term value investments and event-driven special situations.
ContactAgnes CaoKerrisdale Capital email@example.com 212-257-4385
Kerrisdale Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 160804.
View original content:http://www.prnewswire.com/news-releases/sahm-adrangis-kerrisdale-capital-issues-negative-report-on-proteostasis-therapeutics-inc-and-announces-conference-call-schedule-300616553.html
SOURCE Kerrisdale Capital Management, LLC
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All